With private financing from Wellcome Trust, Bill & Melinda Gates Foundation, Woodford Patient Capital Trust plc, Malin Corporation plc, ORI Fund and Hepalink, we can create a mature and long-term vision for success in tackling some of the most challenging diseases.
Our vision is to be a global biopharmaceutical company, an inspirational home of molecular immunology driving the development of novel drug substances.
Fusing passion with compassion, Kymab’s mission is:
- To realise fully the value of antibodies developed using the Kymouse™ platform
- To deliver modern medicines on a unique and proven platform
- To bring hope to patients with high unmet needs
- To treat the world’s diseases, bringing societal benefit
- To be an effective global partner in ameliorating global disease
- To realise unique opportunities for partners and value for investors from our unique approach